Shanghai Fosun Pharmaceutical (Group) (SFOSF) Stock Price, News & Analysis

Company Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is an integrated healthcare conglomerate headquartered in Shanghai, China. A subsidiary of Fosun International, the company engages in research, development, manufacturing and distribution of a broad range of pharmaceutical products and medical services. Its core business operations encompass prescription drugs, over-the-counter medications, active pharmaceutical ingredients (APIs) and biological products, supported by an expanding portfolio of healthcare services.

Operating multiple R&D centers and production facilities across China, Fosun Pharma has developed capabilities in small-molecule and biologics research, as well as in vitro diagnostic devices and medical equipment. The company’s distribution network spans domestic provinces and extends internationally to markets in Asia, Europe, Africa and the Americas. In addition to its pharmaceutical businesses, it has broadened its healthcare footprint through hospital management, clinical contract research services and targeted investments in specialized biotech ventures.

Founded in 1994, Shanghai Fosun Pharmaceutical has grown from a regional drug manufacturer into one of China’s leading pharmaceutical groups. Through both organic innovation and strategic partnerships, the company has secured regulatory approvals for a number of novel therapies and expanded its product pipeline. Under the guidance of its parent group, the firm continues to pursue global collaboration and digital health initiatives aimed at enhancing healthcare delivery and patient outcomes.

Key Stats

• Today's Range: $2.30 to $2.30
• 50-Day Range: $1.96 to $2.67
• 52-Week Range: $1.50 to $2.67
• Volume: 1,268 shs
• Average Volume: 3,983 shs
• Market Capitalization: N/A
• P/E Ratio: 1.97
• Dividend Yield: 11.74%
• Price Target: N/A
• Consensus Rating: N/A

Shanghai Fosun Pharmaceutical (Group) Stock Analysis - MarketRank™

Shanghai Fosun Pharmaceutical (Group) scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shanghai Fosun Pharmaceutical (Group).

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.03.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.14.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Fosun Pharmaceutical (Group) has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shanghai Fosun Pharmaceutical (Group) has recently increased by 4,969.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shanghai Fosun Pharmaceutical (Group) pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shanghai Fosun Pharmaceutical (Group) does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shanghai Fosun Pharmaceutical (Group) is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Fosun Pharmaceutical (Group) has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shanghai Fosun Pharmaceutical (Group) has recently increased by 4,969.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Shanghai Fosun Pharmaceutical (Group) has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shanghai Fosun Pharmaceutical (Group) this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shanghai Fosun Pharmaceutical (Group) insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 4.64% of the stock of Shanghai Fosun Pharmaceutical (Group) is held by institutions.

SFOSF Stock Analysis - Frequently Asked Questions

How have SFOSF shares performed this year?

Shanghai Fosun Pharmaceutical (Group)'s stock was trading at $1.8003 at the start of the year. Since then, SFOSF shares have increased by 27.8% and is now trading at $2.30.

How do I buy shares of Shanghai Fosun Pharmaceutical (Group)?

Shares of SFOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/05/2025
• Next Earnings (Estimated): 8/26/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SFOSF
• CIK: N/A
• Web: www.fosunpharma.com
• Phone: 86-21-3398-7000
• Fax: N/A
• Employees: 40,370
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 1.97
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A